Literature DB >> 3513991

Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding.

F Elferink, W J van der Vijgh, I Klein, H M Pinedo.   

Abstract

Toxicity of cisplatin can be decreased by concomitant administration of sodium thiosulfate, which perhaps chemically inactivates this platinum compound. We studied the disappearance of cisplatin and carboplatin in aqueous solutions of thiosulfate at 37 degrees C by means of liquid chromatography. At initial concentrations that were similar to therapeutic concentrations in plasma, both drugs disappeared, with half-lives of 66 and 537 min for cisplatin and carboplatin, respectively. At higher thiosulfate concentrations, as found in urine, the respective half-lives were 3.7 and 33.8 min. These values suggest that direct chemical interaction in the plasma compartment has limited therapeutic consequences, whereas the anti-toxic effect of thiosulfate might be explained by the rapid inactivation of cisplatin in the kidneys. Reaction products of cisplatin and thiosulfate bound instantaneously and mainly reversibly to plasma proteins. Protein-bound cisplatin was not released by added thiosulfate--which may explain why thiosulfate, to be effective, must be given in advance of and during cisplatin administration.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3513991

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  15 in total

Review 1.  Treatment of advanced head and neck cancer with intra-arterial cisplatin and concurrent radiation therapy: the 'RADPLAT' protocol.

Authors:  P Kumar; K T Robbins
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

2.  Unusual cervical spinal cord toxicity associated with intra-arterial carboplatin, intra-arterial or intravenous etoposide phosphate, and intravenous cyclophosphamide in conjunction with osmotic blood brain-barrier disruption in the vertebral artery.

Authors:  D Fortin; L D McAllister; G Nesbit; N D Doolittle; M Miner; E J Hanson; E A Neuwelt
Journal:  AJNR Am J Neuroradiol       Date:  1999 Nov-Dec       Impact factor: 3.825

Review 3.  Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Authors:  K Hoekman; W J van der Vijgh; J B Vermorken
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

4.  A density functional reactivity theory (DFRT) based approach to understand the interaction of cisplatin analogues with protecting agents.

Authors:  Amrit Sarmah; Ram Kinkar Roy
Journal:  J Comput Aided Mol Des       Date:  2014-09-03       Impact factor: 3.686

5.  Reaction kinetics of cisplatin and its monoaquated species with the (potential) renal protecting agents (di)mesna and thiosulfate. Estimation of the effect of protecting agents on the plasma and peritoneal AUCs of CDDP.

Authors:  O R Leeuwenkamp; W J van der Vijgh; J P Neijt; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 6.  Emerging Therapies for Sensorineural Hearing Loss.

Authors:  Matthew Gordon Crowson; Ronna Hertzano; Debara L Tucci
Journal:  Otol Neurotol       Date:  2017-07       Impact factor: 2.311

Review 7.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

8.  Pharmacokinetics of carboplatin after intraperitoneal administration.

Authors:  F Elferink; W J van der Vijgh; I Klein; W W ten Bokkel Huinink; R Dubbelman; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 9.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.

Authors:  N Nagai; K Hotta; H Yamamura; H Ogata
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.